But this is the reality !!! Even for personalized medicinal products, one makes the trial activities so regulated (for so called "safety") that nobody can pay it anymore and that it stops. Regulations and costs during R&D are a major and independent risk factor for patients.
This comment has been removed by the author.
In a similarly frustrating vein, it looks like Novartis is killing development work on IDH305 for financial reasons too.Hopefully the new FDA head, Gottlieb, will follow thru on some of the claims of streamlining approvals and lowering costs.